A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents
一项针对新诊断的继发性急性髓系白血病 (AML) 以及低甲基化药物治疗失败后的骨髓增生异常综合征 (MDS) 或慢性粒单核细胞白血病 (CMML) 患者的 1/2 期研究,评估阿扎胞苷、维奈托克和培沃地司他联合用药的疗效。
期刊:Journal of Hematology & Oncology
影响因子:40.4
doi:10.1186/s13045-023-01476-8
Short, Nicholas J; Muftuoglu, Muharrem; Ong, Faustine; Nasr, Lewis; Macaron, Walid; Montalban-Bravo, Guillermo; Alvarado, Yesid; Basyal, Mahesh; Daver, Naval; Dinardo, Courtney D; Borthakur, Gautam; Jain, Nitin; Ohanian, Maro; Jabbour, Elias; Issa, Ghayas C; Qiao, Wei; Huang, Xuelin; Kanagal-Shamanna, Rashmi; Patel, Keyur P; Bose, Prithviraj; Ravandi, Farhad; Delumpa, Ricardo; Abramova, Regina; Garcia-Manero, Guillermo; Andreeff, Michael; Cortes, Jorge; Kantarjian, Hagop